Clinical Trials for Non-Small Cell Lung Cancer

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously treated, locally advanced or metastatic, HER2 IHC 3+ solid tumors (excluding biliary tract cancers) who have progressed after at least one prior systemic therapy and lack standard treatment options; patients receive zanidatamab, a bispecific antibody targeting two HER2 epitopes. Eligible patients must have measurable disease, ECOG 0–1, and no active CNS metastases.

ClinicalTrials.gov ID: NCT06695845

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable or metastatic solid tumors harboring homozygous MTAP deletion (biopsy-amenable, ECOG 0-1) are eligible to receive MRTX1719, a selective PRMT5 inhibitor targeting the PRMT5-MTA complex, as monotherapy or in combination with standard therapies in expansion cohorts. Prior PRMT5 or MAT2A inhibitor therapy is excluded.

ClinicalTrials.gov ID: NCT05245500

A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic non-small cell lung cancer—including EGFR-mutant disease post-EGFR TKI, KRAS-G12C-mutant after KRAS-G12C inhibitor, and EGFR-wildtype post-systemic therapy—to receive HER3-DXd (patritumab deruxtecan), an antibody-drug conjugate targeting HER3 and delivering a topoisomerase I inhibitor payload. Treatment is given intravenously every three weeks, with safety, dosing, and activity being evaluated across molecular subtypes.

ClinicalTrials.gov ID: NCT03260491

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are adults with advanced or metastatic EGFR-mutant NSCLC who have progressed after at least 4 months on prior osimertinib. This trial compares quaratusugene ozeplasmid—an IV lipid nanoparticle gene therapy delivering the TUSC2 tumor suppressor gene—plus ongoing osimertinib versus standard platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT04486833

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with metastatic KRAS G12C-mutated NSCLC and untreated brain metastases (up to 10 lesions, none >3 cm), who are either treatment-naïve or have received up to two prior lines of therapy, to receive combination therapy with the selective KRAS G12C inhibitor adagrasib plus stereotactic radiosurgery. Prior KRAS G12C inhibitor therapy is not allowed.

ClinicalTrials.gov ID: NCT06248606

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls treatment-naive adults with advanced nonsquamous NSCLC that is KRAS p.G12C positive and PD-L1 negative, randomizing them to receive either sotorasib (a KRAS G12C inhibitor) plus carboplatin/pemetrexed or pembrolizumab plus carboplatin/pemetrexed.

ClinicalTrials.gov ID: NCT05920356

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic ER+/HER2- breast cancer who have progressed after endocrine therapy and a CDK4/6 inhibitor, as well as selected patients with castration-resistant prostate cancer or non–small-cell lung cancer refractory to standard treatments. Participants receive PF-07248144, a selective KAT6A/B histone acetyltransferase inhibitor, as monotherapy or in combination with endocrine therapy or other investigational agents.

ClinicalTrials.gov ID: NCT04606446

A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with stage IV or recurrent NSCLC with MET amplification (as detected by tissue NGS) who have progressed on at least one prior systemic therapy and have not received MET TKIs or have other actionable mutations are eligible to receive subcutaneous amivantamab, a bispecific antibody targeting EGFR and MET. All participants receive this investigational agent until progression or toxicity.

ClinicalTrials.gov ID: NCT06116682

Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with stage IV NSCLC who have progressed on first-line immunotherapy or chemoimmunotherapy receive a single fraction of spatially fractionated grid radiotherapy to a selected extracranial tumor lesion, followed by five fractions of palliative radiation and continuation of standard immunotherapy. Eligible patients must have at least one lesion ≥3 cm suitable for grid therapy and ECOG 0–2, with controlled brain metastases allowed.

ClinicalTrials.gov ID: NCT06660407

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with relapsed or refractory small cell lung cancer, metastatic castration-resistant prostate cancer post-abiraterone/enzalutamide, or follicular lymphoma to receive mevrometostat, a selective oral EZH2 inhibitor, as monotherapy or in combination with standard of care therapies. Treatment assignment varies by disease type and prior therapy, with some arms randomizing mCRPC patients to mevrometostat plus standard of care versus standard of care alone.

ClinicalTrials.gov ID: NCT03460977